Elanix Biotechnologies

We are a tissue regeneration company dedicated to using innovative cell technologies, advancing patient wound care and healing processes

Elanix develops and markets progenitor cell-based products to help regenerate tissue and promote healing in the treatment of burns, gynecological and dermatological conditions. The Company is headquartered in Nyon, Canton Vaud, Switzerland, with offices in Wiesbaden, Germany, and listed on the Frankfurt stock exchange under the symbol ELN.

Highlights of 2017

A message from Tomas J. Svoboda, CEO

2017 has been a very busy year and I am proud to report Elanix has made important strides and met the crucial business objectives we set to achieve.

As we begin another year, I would like to share some of our past year’s highlights and review the important milestones we passed as a company…


Progenitor cells are fully differentiated yet immunologically neutral cells that are very potent inducers of tissue growth and healing. Elanix enhances the activity of progenitor cells with proprietary cytokine formulations to create unique cell therapy products and procedures.


Elanix owns two specialty cosmetics , GYNrepair® and SKINrepair®, marketed in Switzerland since 2012 in gynecology and dermatology.

Elanix is developing a bioresorbable & bioactive skin dressing derived from progenitor skin fibroblasts to accelerate regeneration and improve quality of skin following acute burns.


Sincopharm SA